Krystal Biotech Q2 2025 net income $38.3M ($1.29 diluted EPS) on $96M VYJUVEK revenue

Krystal Biotech, Inc.

2025-Q2 EPS reported $2.48 revenue$184,225,000

VYJUVEK net product revenue $96.0M in Q2 2025, up from $70.3M in Q2 2024; gross margin 93%.
Net income $38.3M vs $15.6M YoY; basic EPS $1.33, diluted EPS $1.29.
Cash and investments $820.8M; FY 2025 non-GAAP R&D+SG&A guidance $150-175M.
VYJUVEK approved in Japan for DEB patients from birth; launch expected by end of 2025.
First patient dosed in Phase 3 IOLITE study (KB803 for corneal abrasions in DEB) and Phase 2 EMERALD-1 (KB801 for NK).

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.